9.8052
Precedente Chiudi:
$9.85
Aprire:
$9.93
Volume 24 ore:
130.73K
Relative Volume:
0.08
Capitalizzazione di mercato:
$849.74M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-4.5185
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
+0.10%
1M Prestazione:
+19.78%
6M Prestazione:
+70.02%
1 anno Prestazione:
-47.20%
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Confronta KURA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KURA
Kura Oncology Inc
|
9.79 | 854.95M | 0 | -168.09M | -138.01M | -2.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.74 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
461.18 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
550.12 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
329.04 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-09-04 | Iniziato | Guggenheim | Neutral |
2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
2024-10-24 | Iniziato | UBS | Buy |
2024-10-14 | Downgrade | Stifel | Buy → Hold |
2023-12-22 | Iniziato | Mizuho | Buy |
2023-08-11 | Iniziato | BofA Securities | Buy |
2023-07-27 | Iniziato | Scotiabank | Sector Perform |
2023-05-17 | Iniziato | BTIG Research | Buy |
2023-01-31 | Iniziato | Stifel | Buy |
2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
2022-02-15 | Iniziato | Jefferies | Buy |
2021-05-05 | Ripresa | Credit Suisse | Outperform |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2020-12-07 | Reiterato | H.C. Wainwright | Buy |
2020-12-03 | Iniziato | Stifel | Buy |
2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
2020-07-07 | Iniziato | Credit Suisse | Outperform |
2020-05-05 | Iniziato | Barclays | Overweight |
2019-07-18 | Iniziato | Deutsche Bank | Buy |
2018-11-09 | Iniziato | Piper Jaffray | Overweight |
2018-08-01 | Iniziato | H.C. Wainwright | Buy |
2016-10-13 | Ripresa | Leerink Partners | Outperform |
2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
2015-12-30 | Iniziato | Oppenheimer | Outperform |
2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Can Kura Oncology Inc. stock resist market sell offsWeekly Trade Recap & Daily Profit Maximizing Trade Tips - newser.com
Will Kura's Menin Inhibitor Deliver Where Other AML Therapies Fall Short? - RTTNews
Can technical indicators confirm Kura Oncology Inc.’s reversalJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
How sustainable is Kura Oncology Inc. stock dividend payoutJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Predicting Kura Oncology Inc. trend using moving averagesWeekly Stock Analysis & Daily Stock Trend Reports - newser.com
How Kura Oncology Inc. stock reacts to Fed rate cutsEarnings Recap Report & Fast Entry Momentum Alerts - newser.com
Visual analytics tools that track Kura Oncology Inc. performanceJuly 2025 Outlook & Community Supported Trade Ideas - newser.com
What analysts say about Kura Oncology Inc stockPrice Channel Trading & Small Budget Trading Tips - earlytimes.in
Identifying reversal signals in Kura Oncology Inc.2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Custom strategy builders for tracking Kura Oncology Inc.2025 Trade Ideas & Fast Gain Stock Tips - newser.com
Will Kura Oncology Inc. stock reach all time highs in 2025Exit Point & Weekly Watchlist for Hot Stocks - newser.com
Kura Oncology (NASDAQ:KURA) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Advanced analytics toolkit walkthrough for Kura Oncology Inc.Earnings Beat & High Accuracy Swing Trade Signals - newser.com
Kura Oncology (NASDAQ:KURA) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Kura Oncology Inc. recovery potential after sell offMarket Performance Summary & Verified Technical Signals - newser.com
Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - GlobeNewswire Inc.
How Kura Oncology Inc. stock reacts to bond yieldsEarnings Risk Summary & Free Weekly Watchlist of Top Performers - newser.com
Real time social sentiment graph for Kura Oncology Inc.Weekly Investment Report & Verified Entry Point Signals - newser.com
Kura Oncology (NASDAQ:KURA) Trading 8.9% HigherStill a Buy? - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 35,779 Shares of Kura Oncology, Inc. $KURA - MarketBeat
What drives Kura Oncology Inc stock priceEarnings Growth Projections & High Yield Market Growth - earlytimes.in
Kura Oncology, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
What MACD signals say about Kura Oncology Inc.2025 Technical Patterns & Long-Term Safe Investment Plans - newser.com
Can Kura Oncology Inc. stock withstand economic slowdownJuly 2025 WrapUp & Community Trade Idea Sharing Platform - newser.com
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
Kura Oncology Inc. stock prediction for this week2025 Support & Resistance & Fast Entry Momentum Alerts - newser.com
How Kura Oncology Inc. stock performs in rate cut cyclesWall Street Watch & Low Risk High Reward Ideas - newser.com
Will Kura Oncology Inc. bounce back from current supportGap Up & Smart Investment Allocation Insights - newser.com
Is Kura Oncology Inc a good long term investmentCash Flow Trends & View Live Stock Forecasts Instantly - earlytimes.in
Kura Oncology (KURA) Grants Inducement Awards to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
122,250-Option Grant for New Hires: Kura Oncology Grants Options at $9.20, vesting over four years - Stock Titan
Applying chart zones and confluence areas to Kura Oncology Inc.Earnings Risk Report & High Yield Stock Recommendations - newser.com
Kura Oncology, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Kura Oncology at UBS Virtual Oncology Day: Strategic Advances in AML Treatment - Investing.com Canada
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia - MarketScreener
Kura Oncology (KURA) Advances KOMET-007 Trial with First Patient Dosed - GuruFocus
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology and Kyowa Kirin Initiate KOMET-007 Trial Evaluating Ziftomenib in Combination with FLT3 Inhibitors for Frontline Treatment of AML - Quiver Quantitative
Kura Oncology stock maintains Market Outperform rating at Citizens JMP By Investing.com - Investing.com Canada
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Bair Teresa Brophy sells Kura Oncology (KURA) shares for $78,736 By Investing.com - Investing.com Australia
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):